- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07615244
MICROVASCULAR DAMAGE IN THROMBOTIC THROMBOCYTOPENIC PURPURA (MITHO)
STUDY OF MICROVASCULAR DAMAGE IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA
The goal of this interventional, non-pharmacological clinical study is to assess microcirculatory dysfunction in patients with thrombotic thrombocytopenic purpura (TTP), both during the acute phase and in remission, compared with the general population.
Microcirculatory damage will be defined as the presence of at least one abnormal instrumental finding among brain magnetic resonance imaging (MRI), optical coherence tomography angiography (OCT-A), and nailfold videocapillaroscopy.
This is a monocentric, national study including two patient cohorts:
Cohort 1: patients enrolled during the acute phase Cohort 2: patients enrolled during remission Participants will be followed for three years with a total of five study visits.
Researchers will not test any drug but will perform detailed clinical, laboratory, and instrumental assessments to evaluate microvascular involvement over time.
Participants will:
- Undergo clinical evaluation, including internal medicine and neurological assessments
- Provide blood and urine samples for laboratory analyses
- Undergo instrumental examinations such as brain MRI, OCT-A, and nailfold videocapillaroscopy
- Receive psychological/neuropsychological evaluations
- Attend follow-up visits over a 3-year period (at baseline, 3 months [cohort 1 only], 12, 24, and 36 months)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Test diagnostique: Factor VIII (FVIII)
- Test diagnostique: Von Willebrand factor (VWF) antigen
- Test diagnostique: VWF:RCo
- Test diagnostique: VWF-propeptide
- Test diagnostique: VWF multimers
- Test diagnostique: sP-selectin
- Test diagnostique: sCD40L
- Test diagnostique: F1+2
- Test diagnostique: VEGF-A
- Test diagnostique: VCAM
- Test diagnostique: ICAM
- Test diagnostique: IL-1β
- Test diagnostique: IL-6
- Test diagnostique: PTX3
- Test diagnostique: BlyS
- Test diagnostique: Neutrophil elastase and myeloperoxidase (NETs) markers
- Test diagnostique: soluble C5b-9
- Test diagnostique: C5a
- Test diagnostique: NFL
- Test diagnostique: GFAP
- Génétique: Whole exome sequencing - WES
- Test diagnostique: Proteomic Analysis
- Test diagnostique: evaluation of thrombus formation with Total Thrombus formation Analysis System (T-TAS)
- Test diagnostique: Microfluidic Flow Chamber
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Milano
-
Milan, Milano, Italie, 20122
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- aged ≥18 years
- diagnosis of TTP (either congenital or acquired immune-mediated TTP)
- referred at our hospital (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, S.C. Medicina - Emostasi e Trombosi)
- providing a signed informed consent
Exclusion Criteria:
- Patients who do not possess the above inclusion criteria
- Patients who have known contraindications to the instrumental exam included in the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Acute TTP
Patients enrolled during acute phase (cohort 1), T0= within 15 days from hospital admission.
|
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
|
|
Autre: Remission TTP
Patients enrolled during clinical remission (cohort 2), T0= check-up visit performed at more than 3 months from clinical response of the previous episode
|
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
The study is defined as interventional because it includes assessments that are not part of routine clinical practice
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence
Délai: From enrollment to the last visit (after 36 months from Time 0)
|
Prevalence of microcirculation damage in iTTP patients compared to general population
|
From enrollment to the last visit (after 36 months from Time 0)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cerebral microcirculation lesions
Délai: From enrollment to the last visit (after 36 months from Time 0)
|
Evaluate cerebral microcirculation lesions (via brain MRI) in both acute and remission phases of TTP to monitor organ damage progression over time
|
From enrollment to the last visit (after 36 months from Time 0)
|
|
Retinal microcirculation changes
Délai: From enrollment to the last visit (after 36 months from Time 0)
|
Assess retinal microcirculation changes (using OCT and OCT-A) during acute and remission phases of TTP to track organ damage evolution
|
From enrollment to the last visit (after 36 months from Time 0)
|
|
Peripheral microcirculation
Délai: From enrollment to the last visit (after 36 months from Time 0)
|
Analyze peripheral microcirculation (with nailfold videocapillaroscopy) in acute and remission phases to evaluate progression of organ involvement in TTP
|
From enrollment to the last visit (after 36 months from Time 0)
|
|
Association between cerebral MRI lesions and cognitive or psychological symptoms
Délai: From enrollment to the last visit (36 months from Time 0)
|
Explore the relationship between cerebral MRI lesions and cognitive or psychological symptoms during TTP remission, assessing symptom progression
|
From enrollment to the last visit (36 months from Time 0)
|
|
Modification of preclinical biomarkers
Délai: From enrollment to the last visit (36 months from Time 0)
|
Explore the modification of preclinical biomarkers over time at different stage of the disease
|
From enrollment to the last visit (36 months from Time 0)
|
|
Associations between preclinical biomarkers and microcirculatory damage
Délai: From enrollment to the last visit (36 months from Time 0)
|
Identify associations between preclinical biomarkers and microcirculatory damage in both acute and remission phases of TTP to predict risk and progression
|
From enrollment to the last visit (36 months from Time 0)
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Cytopénie
- Processus pathologiques
- Hémorragie
- Manifestations cutanées
- Maladies hématologiques
- Troubles de la coagulation sanguine
- Troubles des plaquettes sanguines
- Microangiopathies thrombotiques
- Purpura thrombocytopénique
- Purpura
- Thrombocytopénie
- Thrombophilie
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Maladies hémiques et lymphatiques
- Purpura thrombotique thrombocytopénique
- Techniques d'investigation
- Techniques génétiques
- Analyse de séquence
- Analyse de séquence, ADN
- Séquençage du génome entier
- Séquençage d'exome
Autres numéros d'identification d'étude
- IRCCSMaggioreH (IRCCSMaggioreH)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .